Background-Network-based approaches may leverage genome-wide association (GWA) analysis by testing for the aggregate association across several pathway members. We aimed to examine if networks of genes that represent experimentally determined protein-protein interactions (PPIs) are enriched in genes associated with risk of coronary heart disease (CHD). Methods and Results-Genome-wide association analyses of approximately Ϸ700 000 single-nucleotide polymorphisms in 899 incident CHD cases and 1823 age-and sex-matched controls within the Nurses' Health and the Health Professionals Follow-up Studies were used to assign genewise P values. A large database of PPIs was used to assemble 8351 unbiased protein complexes and corresponding gene sets. Superimposed genewise P values were used to rank gene sets based on their enrichment in genes associated with CHD. After correcting for the number of complexes tested, 1 gene set was overrepresented in CHD-associated genes (Pϭ0.002). Centered on the ␤1-adrenergic receptor gene (ADRB1), this complex included 18 protein interaction partners that have not been identified as candidate loci for CHD.
G enome-wide association (GWA) studies provide a unique opportunity for the unbiased exploration of novel genetic variation of importance to phenotypic traits. The first series of GWA studies of coronary heart disease (CHD) and more broadly defined cardiovascular disease (CVD) phenotypes elucidated DNA sequence variations at the 9p21.3 locus as a robustly replicated risk-conferring region, [1] [2] [3] but through a series of larger GWA study consortia, approximately 10 susceptibility loci have been reported. 4 -6 The recent publication of results from the multi-ethnic Coronary Artery Disease Genetics Consortium, 7 the first Han Chinese GWA study, 8 and the CARDIoGRAM consortium with Ͼ20 000 coronary artery disease cases, 9 yielded an additional 18 new loci. However, the complexity of the phenotype, 10 small effect sizes, and between-study differences may complicate the identification of many true associations in meta-analyses that necessarily assume homogeneity across the individual studies. Most GWA studies have focused on the identification of the strongest single-locus associations, but the identification of combined effects of many weakly associated variants is especially appealing for complex diseases, such as CHD, that are likely not caused by single variants or by a single biological pathway. Thus, another suggested approach for reducing the noise inherent in moderately powered highdensity data collected within internally homogeneous populations is the integration of additional biological data on pathway organization through the use of protein-protein interaction (PPI) databases. [11] [12] [13] [14] [15] [16] By enabling tests of sets of single-nucleotide polymorphisms (SNPs) within physically interacting gene products (direct or indirect), PPI data can augment GWA analysis because a set of SNPs, each with a moderate, but genuine, association, in aggregate may have improved statistical significance. Although several databases provide gene sets that resemble well-known canonical pathways, high-confidence PPI data may, to a larger degree, mimic the unbiased nature of GWA studies because of their increased coverage and detail of even noncanonical pathways. 11, 17 Initial approaches have proved useful for suggesting novel genes and gene networks involved in other complex phenotypes, such as obesity, 18 type 2 diabetes mellitus, 13 breast and pancreatic cancer, 19 multiple sclerosis, 20 and Crohn disease, 21 that were not identified in the traditional GWA analysis. The completeness of such integrative analysis relies strongly on the gene sets tested. We aimed to examine if networks of genes that represent experimentally determined PPIs are enriched in genes associated with the risk of incident CHD. To leverage our GWA analysis of CHD within 2 homogeneous US prospective cohorts, including 899 incident cases collected through Ͼ10 years of follow-up, we used our PPI database InWeb, 14 which covers approximately Ϸ13 000 human proteins and 173 500 high-confidence experimentally derived PPIs based on 11 publicly available PPI databases.
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Methods
Study Population
The Nurses' Health Study (NHS) enrolled 121 701 female nurses, aged 30 to 55 years, who returned a mailed questionnaire in 1976 regarding lifestyle and medical history. The Health Professionals Follow-up Study (HPFS) enrolled 51 529 males, aged 40 to 75 years, who returned a similar questionnaire in 1986. Participants of both cohorts have received follow-up questionnaires biennially to record newly diagnosed illnesses. Detailed descriptions of the study cohorts have been previously published. 22, 23 Blood Collection and DNA Extraction in a Nested Case-Control Study Between 1989 and 1990 , a blood sample was requested from all active participants in the NHS and collected from 32 826 women. Similarly, blood samples were requested between 1993 and 1995 and obtained from 18 225 HPFS participants. For details on storage of blood samples, please see the online supplement.
In both cohorts, nested case-control studies were designed using incident CHD, with nonfatal myocardial infarction and fatal CHD as the outcome. A diagnosis of myocardial infarction was confirmed on the basis of the criteria of the World Health Organization (symptoms plus either diagnostic electrocardiographic changes or elevated levels of cardiac enzymes). Deaths were identified from state vital records and the National Death Index or reported by the participant's next of kin or the postal system. A fatal CHD was confirmed by an examination of hospital or autopsy records, by the listing of CHD as the cause of death on the death certificate, if CHD was the underlying and most plausible cause, and if evidence of previous CHD was available. Among participants who provided blood samples and who were free of diagnosed CVD or cancer at blood draw, we identified 474 women and 454 men with incident CHD between blood draw and June 2004. By using risk-set sampling, 24 controls were selected randomly and matched in a 1:2 ratio on age, smoking, and month of blood return, among participants who were free of CVD when CHD was diagnosed in the case. In this study design, a control for an early case may be included again if the person develops CHD during follow-up; thus, after counting such converters only once (as cases), the total number of samples sent for genotyping were 1354 HPFS samples and 1521 NHS samples.
The present study was approved by the institutional review boards at Brigham and Women's Hospital and Harvard School of Public Health.
Genotyping and Quality Control
Details on the protocol for DNA extraction have been included in the online supplement. Genotyping was performed using the Affymetrix Genome-Wide Human 6.0 array and the Birdseed calling algorithm. 25 Genotypic data for 1330 HPFS samples (98%) passed laboratory technical quality control criteria, and the missing call rate was Ͻ0.05. Likewise, 96% of the NHS samples were successfully genotyped. A subset of 312 NHS samples were not genotyped, together with the remaining CHD case-control sets, because they overlapped with previous GWA studies of breast cancer (Illumina 550) and type 2 diabetes (Affymetrix 6.0). These samples were processed and subjected to quality control as part of the earlier GWAS (leaving 272 samples with available data), and SNPs also present on the Affymetrix 6.0 platform were subsequently merged with the cleaned CHD data. Details on methods for data cleaning and assessment of population structure in the data sets are included in the online supplement. Because of few samples with substantial evidence of non-European genetic ancestry, these samples were excluded from subsequent analysis (nϭ24 
GWA Analysis of CHD
To analyze the association between each SNP (coded as counts of minor alleles) and risk of CHD, we ran logistic regression analysis using PLINK software. 26 We adjusted for matching factors used in the design of the nested case-control study (age and smoking) and the top 3 eigenvectors. We also analyzed the MACH dosage files of the imputed SNPs (with MAF Ն0.05) in logistic regression models (adjusting for the same covariates as previously given) using the ProbABEL package from the ABEL set of programs. 27 A fixedeffects meta-analysis was performed to combine the study-specific ␤ estimates using the METAL package. 28 Systems biology-based approaches that integrate data on protein interactions are necessarily restricted to the protein-coding part of the genome. We mapped all GWA SNPs that passed quality control to 21 800 protein-coding genes (423 450 mapped SNPs, approximately Ϸ57% of all SNPs on the Affymetrix 6.0 arrays) ( Figure 1, step 1 ). This process is gene centric such that SNPs that are not within genes or their 70-kb upstream and 20-kb downstream flanking regions were discarded. SNPs were allowed to map to Ͼ1 gene. Each gene was assigned a P value based on the SNP with the lowest GWA P value within the gene transcript(s) and its flanking regions. Subsequently, the Š idàk correction was applied to adjust the P value for each gene by the number of effective tests (uncorrelated number of SNPs within each gene and its flanking regions, as described by Galwey, 29 and provided as a web tool through MetaRanker). 16 
PPIs and CHD-Specific Protein Complexes
Protein-protein interactions comprise both transient interactions (eg, phosphorylation events) and stable interactions (eg, the cytoskeleton). Our comprehensive, experimentally derived database of protein-protein interactions, InWeb (version 2.9), covers approximately Ϸ13 000 human proteins and 350 029 PPIs, of which 173 500 can be regarded as high-confidence interactions (as described later). 14 The database is updated on a monthly basis with interactions retrieved from all major experimental PPI databases (details available in the online supplement). The strengths of the InWeb database include the relatively high coverage (4-fold increase in the number of interactions compared with the Human Protein Reference Database) 30 and a quantitative assessment of confidence in the reported interactions. The (continuous) confidence score (ranging from 0 [low support] to 1 [strong support]) is assigned by accounting for the number and quality of the publications reporting each of the interactions and the number of shared interaction partners of 2 interacting proteins. 14 The assembly of 8351 gene sets was accomplished by iteratively assigning each protein in the database and its first-order interaction partners to a protein complex ( Figure 1, step  1b ). As such a construction of protein complexes results in a relatively large number of overlapping complexes; complexes that were Ͼ80% similar (similarity of gene sets assessed by the Jaccard Index) were merged. After superimposing the genewise P values from the GWA analysis onto the network, we used a modified version of an approach published by Ideker et al 31 to iteratively assess whether any of the gene sets that were derived from the protein complexes were enriched in CHD-associated genes. Given a gene set of size k, this was accomplished as follows: (1) converting all k gene P values to Z scores using the inverse normal cumulative distribution function, (2) weighting them with the interaction confidence score of the PPI with the central hub protein (a step that was not part of the original algorithm), (3) calculating a gene-set score by summing the weighted Z scores, and then (4) subtracting the sum of an average gene set of size k (calculated based on 100 000 randomized gene-set scores) and dividing by the SD of an average subnetwork of size k. Formally, step 1 can be formulated as the confidence score for the PPI between interacting gene product j and the hub gene product, S gene-set denotes the score of the gene set after steps 1 to 4, k and k denote the mean and SD of 100 000 randomized gene-set scores, and Z gene-set denotes the final gene-set Z score. By using this method, all gene sets were ranked based on their computed Z scores (Figure 1, step 3) . Because SNPs were allowed to map to several overlapping genes, some gene sets may be assigned artificially inflated scores if they comprise genes that overlap on a given chromosome and are scored based on the same low SNP P value. To avoid this potential bias, we discarded 1 of the genes in any overlapping gene pair in a given complex (genes were considered to overlap if their transcripts were closer than 200 kb to each other). This approach is conservative because it avoids inflated complex scores, but in some cases it may reduce the significance of truly associated complexes that comprise colocalizing gene products with independent associations. In our present analysis, the top complex remained the same with or without discarding overlapping genes (and for different exclusion thresholds). We assessed the significance of our observed topscoring complex by comparing its score with a background distribution of 100 scores generated under the null hypothesis that the complex is not associated with CHD case-control status. The background distribution was estimated on the basis of 100 permutations of our GWA meta-analysis (randomizing the case-control status) and recomputations of the gene scoring and complex scoring step for each permutation. An ideal scenario would include at least 1 million permutations, but the aggregate computing times for the GWA analysis, the gene scoring step, and the complex enrichment analysis did not allow for this.
After identification of the top-ranking complex, we searched the literature to see if the genes were known as human CVD candidate genes. To assess overrepresentation of known CVD susceptibility genes, we used a list of 123 genes reported by Samani et al 3 and updated it with GWA findings in the National Institutes of Health Catalog of GenomeWide Association Studies (supplemental Table I ). 32 We also tested for overrepresentation of a list of 889 genes that affected cardiovascular system physiological features (MP:0001544) in knockout mice (Mouse Genome Informatics database, http://www.informatics.jax.org; Jackson Laboratory, Bar Harbor, ME), of which 837 were among the gene products in our PPI database. To ensure that the observation that genes from our top complex were overrepresented in the mouse cardiovascular physiological gene set was not because of chance, we compared the observed enrichment score with a background distribution of 10 000 scores computed based on randomly sampled protein complexes. Each of the random complexes matched the observed complex in size, and each gene product was sampled with a probability equal to its observed prevalence in the total set of protein complexes. In addition to the enrichment analysis of known human and mouse CHD risk genes, we used the Ingenuity Pathway Analysis (IPA) software tool, version 9.0 (Ingenuity Systems Inc, 2011) to systematically test the complex genes for pathway enrichment.
Results
The characteristics of incident cases and matching controls in the 2 cohorts are presented in Table 1 . The women in the NHS were slightly younger, more likely to smoke, and more likely to report a diagnosis of hypertension or diabetes. Genome-wide association analysis of each cohort separately and in a meta-analysis did not reveal any markers that exceeded the genome-wide significance threshold (supplemental Figure I ).
Based on the InWeb database, 8351 protein complexes were assembled based on large-scale proteomics data from human and model organisms. We restrained our analyses to high-confidence PPIs only, including a subset that we recently validated experimentally in human heart tissue. 39 The resulting protein complexes were tested for enrichment in CHD-associated genes by using the genewise P values from the GWA analysis to create Z scores and ranking the complexes (gene sets) by their combined Z scores, adjusted for the size of each gene set and weighted by the confidence of the interactions between the peripheral gene products and the central protein of the complex. After correcting for the number of complexes tested, 1 gene set was significantly overrepresented in CHD-associated genes from our GWA meta-analysis (Pϭ0.002). The gene complex was centered on the known candidate gene for the ␤1-adrenergic receptor (ADRB1) (Figure 2 ). To ensure that the top complex was not merely significantly enriched in genes with low P values but was significantly associated with CHD case-control status, we permuted the phenotype-genotype association in the GWA analysis 100 times and recomputed the complex score at each iteration. We found that the score for the observed ADRB1 complex was superior to any of the scores for the randomized complexes. In Figure 2 , the additional 18 genes that were part of the complex of interacting proteins are shown. Edges between them are scaled in size according to our confidence measure. As shown in more detail in Table 2 , the genes (membrane-associated guanylate kinase inverted 1 [MAGI1], the protein kinase cAMP-dependent catalytic ␣ [PRKACA], and the Golgi-associated PDZ and coiled-coil motif containing [GOPC]) were nominally significant after correcting for the number of independent SNPs in each gene, whereas the remainder showed weaker or no association. In the combined test of a gene set, all known interaction partners are included regardless of their GWA signal, and the strength of the association for the complex relies on the sum of all genewise P values of the interacting genes. Our results did not change when we based our analysis on the imputed GWA data rather than on the hard-call genotypes.
Next, we assessed whether the ADRB1 complex was enriched in known human or mouse CVD risk genes. No significant overlap with the list of 123 susceptibility genes reported by Samani et al 3 and the genetic loci identified in GWA studies of CVD was observed (Pϭ0.1). 32 To test for enrichment in CHD-specific evidence from mouse studies, we searched for the genes in the top complex in an a prioridefined set of genes causing abnormal cardiovascular physiological features in knockout mice. Among 889 genes reported for that phenotype, 837 human homologs were among the 12 793 genes included in our analysis, and 5 were part of the 19 genes in the ADRB1 complex, representing a 4-fold enrichment (Fisher exact test, Pϭ0.006). The 5 genes also found in mice knockout gene sets were ADRB1, ADRA2A, ARRB1, PDE4D, and GRB2, of which all except PDE4D played a role in the regulation of blood pressure, cardiac function, and hypertrophy. Because proteins that are known to interact physically are more likely to have similar functional annotation, 33 possible chance correlations resulting in a gene with a low P value could potentially result in a falsely associated complex if the falsely associated gene's annotation resembles the phenotype of interest. To test for this possible bias, we subjected the mouse gene set enrichment analysis to 10 000 random complexes sampled from the PPI network and found that only 13 of the 10 000 randomized enrichment scores were lower than our observed score (Pϭ0.001). Values are means (SDs) of continuous covariates (except triglyceride levels, which are reported as median ͓interquartile range͔) or percentages. Age and smoking were matching factors. Triglyceride levels were log transformed before analysis and only reported in fasting participants (HPFS, 65%; NHS, 79%). BMI, body mass index; HDL, high-density lipoprotein.
*Self-reported diagnosis before blood draw. We used IPA to examine whether the annotations of the genes in the ADRB1 complex were enriched for any particular phenotype. Between 10 and 12 of the 19 genes were reported in cardiovascular, neurological, endocrine, and immunologic disorders (Table 3) . Moreover, several cardiovascular-related pathways were enriched in genes from the complex. The top canonical pathway was cardiac hypertrophy signaling. To better ensure that the observed enrichment was not because of chance, we sampled 100 random gene sets comprising 19 genes each and performed IPA analysis based on each set. Only 1 random gene set exhibited enrichment in CVD genes as strong as the observed enrichment for the ADRB1 complex gene set. Thus, we conclude that our top complex was significantly enriched in genes associated with CVD (PϽ0.05). None of the random gene sets were significantly enriched in the cardiac hypertrophy canonical pathway, suggesting that the ADRB1 complex gene set was significantly enriched in genes from this pathway as well. We confined this IPA permutation analysis to 100 iterations because the software does not allow automation and all runs were performed manually.
Discussion
We conducted a protein network-based GWA analysis to leverage our moderately powered GWA study of CHD. By using GWA data from 2 individually homogeneous studies, we integrated the genewise P values with a large database of PPIs. By exploiting the complementary nature of genetic variation and biochemical data, we successfully identified a gene complex of 19 candidate genes that may play a role in the etiology of incident CHD. Subsequent pathway enrichment analysis indicated that the top complex was significantly enriched in (1) genes from the canonical cardiac hypertrophy signaling pathway (the highest-ranking pathway in the IPA analysis), (2) genes annotated with CVD (the second most enriched trait in the IPA analysis), and (3) mouse genes annotated in cardiovascular system physiological features. Our results provide preliminary evidence that known CHD-related genes coalesce onto distinct protein complexes. Most of the genes in the top complex had relatively small effect sizes, making them unlikely findings in traditional single-locus GWA analyses of CHD.
To our knowledge, our study of incident CHD is the first attempt at integration of data on the human interactome with GWA data in relation to incident CHD. As shown in the enrichment analyses, the top complex comprises several genes that previously have been annotated to CVD and, in particular, the cardiac hypertrophy signaling pathways. Except for ADRB1, these known genes were not nominally significant by themselves but were leveraged because of their interaction with genes that comprised SNPs, which exhibited an association with CHD in our GWA study. In addition, the top complex was significantly enriched in genes from the Mouse Genetics Initiative database that were annotated in the "cardiovascular system physiology."
The genes ADRB1, GRB2, and ADRA2A overlapped between all 3 a priori-defined gene sets (overview provided in Table  4 ). It is well-known that the ␤1-adrenergic receptor plays an important role in the regulation of cardiac contractility. In candidate genetic studies, ADRB1 SNPs have been associated with blood pressure 34 and risk of future CHD, which might be particularly true for individuals with an elevated blood pressure. 35 Studies on the adrenergic pathway genes, including ADRA2A, that encode the ␣2A-adrenergic receptor, have not shown consistent associations. However, recently, a polymorphism in ADRA2A that caused overexpression of the protein strongly reduced insulin secretion from pancreatic cells and was associated with an elevated risk of type 2 diabetes. 36 The GRB2 gene encodes the growth factor receptor-bound protein 2. So far, information on this genetic locus links it to an important role in lymphocytes and growth cells, but no human genetic epidemiological studies have investigated this locus in relation to cardiometabolic disorders. Alternative approaches for augmenting GWA data by testing significance beyond single-locus associations include pathwaybased approaches, such as methods that search the protein interactome for dense subnetworks enriched in the GWA signal 19, 20 and methods that assess predefined gene sets for enrichment in the GWA signal. 16, 17, 37 The former class of methods is inspired by the early work of Ideker 31 and Chuang 38 and colleagues and uses a heuristic search algorithm to identify subnetworks that are enriched in gene products that, in aggregate, associate with the phenotype. The advantage of these methods is that they do not assume any a priori delineation of pathways. However, the main drawback is that they rely on user-specified parameters that control the size of the subnetworks identified by the algorithm. In addition, none of them incorporate information on the confidence of the experimentally derived PPIs. Although our approach resembles the recently presented dmGWAS approach, 19 only our approach incorporated a score on confidence in the reported interactions. Another strength of our approach is that it is based on a PPI database that, despite its high coverage (our analysis includes twice as many interactions as those used in the dmGWAS method), solely includes high-confidence experimentally derived interactions. Although InWeb does not rely on predicted PPIs, which are more prone to false-positive interactions, it still entails approximately 173 500 interactions from 11 databases. Our integrationbased approach has strengths and limitations. One of the inherent limitations is that it only covers approximately 60% of all SNPs present on genotyping platforms. Consequently, SNPs within distal enhancer regions are discarded, as are other long-range regulatory relationships. However, systematic tissue-and condition-specific expression quantitative trait loci analyses are increasingly contributing to the development of more refined SNPs to gene-mapping schemes. Among other limitations, we had a relatively small sample size in our GWA study of incident CHD and we were limited to whites. However, the application of the novel PPI approach still allowed us to uncover gene sets that were not otherwise identified. Replication in another prospective study setting is important to verify and demonstrate the significance of the ADRB1 complex in incident CVD. Genome-wide data in a cohort with prospectively collected CHD cases would be preferable. It is likely that only larger GWA consortia will have a sufficient number of incident cases to accomplish this. Other approaches to follow up on our proof-of-principle approach and findings include investigations of rare variants through targeted resequencing or expression profiling across CHD-relevant tissues from appropriate cases and controls.
In conclusion, our approach suggests that integration of other layers of biological evidence with a moderately powered GWA study of CHD in 2 homogeneous study populations can yield potentially interesting sets of candidate genes that would be missed in traditional statistical GWA analyses. We identified 1 gene set, centered on ADRB1, that was overrepresented in CHD-associated genes in our GWA study and that was also enriched in genes involved in the CVD phenotype and particularly in blood pressure regulation pathways. Our novel approach highlighted 19 genes that warrant further association and functional studies in terms of risk of CHD and blood pressure.
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